Skip to main content

Health condition

Rapid access breast clinics, two-week-wait referral, triple assessment and result.

A symptomatic breast clinic is not the same as screening. Around nine in ten lumps assessed here turn out to be benign, and the pathway is designed to sort that out quickly.

What happens on the day
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE NG12, the Association of Breast Surgery and the Royal College of Radiologists.

  • 03

    Current for 2026

    Reflects modern one-stop clinic workflow, triple assessment scoring and contemporary molecular subtyping.

Key facts

The two-week-wait pathway at a glance.

What a UK rapid access symptomatic breast clinic is, who is referred and what usually happens on the day.

  • What it is

    A symptomatic breast clinic run under the two-week-wait pathway for suspected cancer, defined by NICE NG12. It is not the same as NHS breast screening.

  • Who is referred

    Anyone with new symptoms that meet NICE criteria, such as a lump, nipple change, skin change or unexplained axillary lump.

  • One-stop model

    Most units offer triple assessment on the same visit: history and examination, imaging and, when indicated, a needle biopsy.

  • Reassurance rate

    Around nine in ten breast lumps assessed in these clinics turn out to be benign.

  • Result timing

    Biopsy results are usually available within five to seven working days at a follow-up appointment led by the breast MDT.

  • Not screening

    Screening is for well women without symptoms. Symptomatic clinics assess people who already have a concern.

Why this guide matters

A pathway designed to give a clear answer, quickly.

Rapid access clinics exist to move suspected cancer through examination, imaging and biopsy in one visit, and to reassure the majority who do not have cancer.

  • Speed by design

    The two-week-wait target and one-stop model reduce the time spent waiting for answers.

  • Triple assessment

    Combining clinical, imaging and pathology scoring is the gold standard for accurate diagnosis.

  • Most results are benign

    Around nine in ten lumps assessed in symptomatic clinics turn out to be benign findings such as fibroadenoma or cyst.

What happens on the day

From referral to a triple assessment result.

The steps a UK symptomatic breast clinic will normally follow, in order, so you know what to expect at each stage.

  1. 01

    Referral

    Two-week-wait referral

    Your GP sends an urgent suspected cancer referral under NICE NG12. The clinic contacts you with an appointment, usually within fourteen days.

  2. 02

    Referral

    History and examination

    A breast surgeon or clinical nurse specialist takes a full history and examines both breasts and the axillae.

  3. 03

    Referral

    Clinical scoring (C1 to C5)

    Findings are scored from C1 (normal) to C5 (malignant) to structure the rest of the visit.

  4. 04

    Investigations

    Imaging on the same visit

    Bilateral mammogram (MLO and CC views) over 40, ultrasound of breast and axilla, with tomosynthesis or contrast-enhanced mammography where available. Under 40, ultrasound is usually first line.

  5. 05

    Investigations

    Needle biopsy if indicated

    Core biopsy for solid lesions, fine needle aspiration for simple cysts or nodes, and vacuum-assisted biopsy for microcalcifications.

  6. 06

    Result

    Triple assessment concordance

    Clinical, radiology (R or M or U 1 to 5) and pathology (B1 to B5) scores are combined. Discordant results are re-reviewed.

  7. 07

    Result

    MDT result appointment

    Results are usually shared within five to seven working days at a follow-up visit, with a clinical nurse specialist present.

Typical timeline: seen within two weeks, biopsy result in five to seven working days.

Who is referred

The NICE NG12 referral criteria.

The symptoms and signs that meet the threshold for an urgent two-week-wait referral to a symptomatic breast clinic.

  • New breast lump age 30 or over

    An unexplained lump in anyone aged 30 or above meets the NICE criterion for a two-week-wait referral.

  • Nipple change age 50 or over

    Unilateral discharge, retraction or a new skin change of the nipple in this age group prompts urgent referral.

  • Younger patient with a lump

    Under 30, an unexplained breast lump is considered for referral if it feels clinically suspicious.

  • Skin changes

    Peau d’orange, ulceration or eczematous change of the nipple (Paget’s disease) needs prompt specialist review.

  • Unexplained axillary lump

    A persistent lump in the armpit in an adult aged 30 or over should be assessed under the same pathway.

  • Inflammatory changes

    A hot, swollen, red breast that does not settle with antibiotics needs urgent specialist assessment.

  • Male breast lump

    Any new breast lump in a man merits referral, especially with skin or nipple change.

  • Red flag · rapid change

    Rapid growth, skin tethering, fixed mass or bloody nipple discharge should be flagged immediately.

Reassurance

Most lumps are benign.

Around nine in ten lumps assessed in a symptomatic clinic are benign. The common non-cancer diagnoses include:

  • Fibroadenoma

    A smooth, mobile lump made of fibrous and glandular tissue, common in younger women.

  • Cyst

    A fluid-filled sac, often tender and cyclical, easily confirmed and drained on ultrasound.

  • Fibrocystic change

    Lumpy or nodular breast tissue that varies with the menstrual cycle.

  • Duct ectasia

    Widening of the ducts behind the nipple that can cause discharge or a lump.

  • Fat necrosis

    A firm lump that follows trauma, surgery or radiotherapy and can mimic cancer on imaging.

  • Mastitis and abscess

    Inflammation or infection of breast tissue, sometimes needing antibiotics or drainage.

  • Intraductal papilloma

    A benign wart-like growth inside a duct that can cause bloody nipple discharge.

  • Phyllodes tumour

    An uncommon fibroepithelial tumour, usually benign but sometimes borderline or malignant.

  • Mondor’s disease

    Superficial thrombophlebitis of a breast vein, felt as a tender cord under the skin.

If cancer is found

Staging, subtyping and genetics.

A diagnosis triggers a coordinated set of tests to characterise the tumour and plan personalised treatment.

  • MDT discussion

    Your case is reviewed by a multidisciplinary team of surgeons, oncologists, radiologists, pathologists and specialist nurses.

  • Local staging

    Bilateral breast MRI is used selectively to define the extent of disease before surgery.

  • Systemic staging

    CT of the chest, abdomen and pelvis and a bone scan are used in higher risk disease. PET-CT is reserved for selected indications.

  • Molecular subtyping

    Testing for ER, PR, HER2 and Ki-67 defines biology and drives treatment choice.

  • Genomic tests

    Oncotype DX, MammaPrint or Prosigna may be used to guide chemotherapy decisions in hormone receptor positive early disease.

  • Genetic counselling

    Considered for BRCA1, BRCA2, PALB2, CHEK2, ATM and TP53 when Manchester criteria, age under 45, triple negative, bilateral, male or Jewish ancestry apply.

Treatment

The building blocks of modern breast cancer care.

Treatment is personalised to tumour biology, stage and your wishes. Most plans combine local treatment (surgery and radiotherapy) with systemic therapy.

  • Surgery

    Breast conserving surgery or mastectomy, with sentinel lymph node biopsy or axillary clearance where indicated.

  • Radiotherapy

    Whole breast, partial breast or chest wall radiotherapy after surgery, tailored by risk and tumour biology.

  • Endocrine therapy

    Tamoxifen, aromatase inhibitors, ovarian suppression or LHRH agonists for hormone receptor positive disease.

  • Chemotherapy

    Neoadjuvant or adjuvant regimens for higher risk disease, guided by molecular subtype and staging.

  • HER2 targeted therapy

    Trastuzumab, pertuzumab, T-DM1 and T-DXd for HER2 positive tumours, alone or with chemotherapy.

  • CDK4/6 inhibitors

    Palbociclib, ribociclib or abemaciclib with endocrine therapy for hormone receptor positive advanced or high risk early disease.

  • PARP inhibitors

    Olaparib or talazoparib for germline BRCA associated disease meeting eligibility criteria.

  • Immunotherapy

    Pembrolizumab, most often combined with chemotherapy, in eligible triple negative breast cancer.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or breast team knows your history and can tell you which parts apply to you. If you are worried about a new breast symptom, ask to be seen.

  • NICE. Suspected cancer: recognition and referral (NG12).

  • NICE. Early and locally advanced breast cancer: diagnosis and management (NG101).

  • Association of Breast Surgery. Best practice guidelines for symptomatic breast clinics.

  • Royal College of Radiologists. Guidance on breast imaging and reporting.

  • Cancer Research UK. Patient information on the two-week-wait pathway and one-stop clinics.

Red flags

When symptoms need urgent review.

These features either meet two-week-wait criteria outright or should be escalated quickly if you are already under follow-up.

  • Inflammatory breast cancer

    A rapidly progressive red, swollen breast, often without a discrete lump, that does not respond to antibiotics.

  • Paget’s disease of the nipple

    Eczema-like nipple change, sometimes with bleeding or crusting, that can signal underlying malignancy.

  • Fixed or matted lymph nodes

    Hard, fixed axillary or supraclavicular nodes warrant urgent specialist review and staging.

  • Spontaneous bloody nipple discharge

    Especially when unilateral and from a single duct, this needs prompt breast clinic assessment.

  • Rapidly growing lump

    Any lump that is clearly enlarging over weeks should be assessed without delay.

  • Skin ulceration or tethering

    Skin dimpling, tethering to underlying tissue or ulceration suggests advanced local disease.

  • Male breast lump with skin change

    Male breast cancer is uncommon but real and can present with a firm retroareolar lump and skin change.

  • Strong family history triggers

    Young age at diagnosis, bilateral disease, triple negative pathology or Jewish ancestry may meet genetic testing criteria.

  • Recurrent symptoms after benign result

    New or changing symptoms in the same area should be re-referred, even after a previous benign result.

Preparing for the clinic

A stressful visit, made easier to navigate.

Four small things that make a real difference on the day and while you wait for results.

A quiet reminder

Anxious does not mean unsafe.

Feeling anxious about a referral is normal. Being referred is not itself a diagnosis. The clinic exists to sort this out for you.

  1. 01 Prepare

    Bring a companion

    Clinics can feel intense. A partner, friend or family member can help you take in information and take notes.

  2. 02 Ask

    Ask about your scoring

    Understanding your C, R or M or U and B scores helps you follow the plan and know what changes matter.

  3. 03 Support

    Use the breast CNS

    Your clinical nurse specialist is a point of contact for questions between visits and after any result.

  4. 04 Wellbeing

    Look after yourself

    Sleep, gentle movement and honest conversations with people you trust matter through the wait for results.

Frequently asked

Everything we get asked about rapid access breast clinics.

Quick answers on the pathway, what to expect and what your result means.

  • What is a rapid access breast clinic?

    It is a symptomatic breast clinic run under the two-week-wait pathway. Your GP refers you when NICE NG12 criteria are met and the clinic aims to see you within fourteen days for triple assessment.

  • How is it different from breast screening?

    Screening is for well women without symptoms and is offered by the NHS Breast Screening Programme. A rapid access clinic assesses people who already have a symptom or clinical concern.

  • What happens at a one-stop appointment?

    You will usually have a history and examination, imaging (mammogram, ultrasound and sometimes tomosynthesis or contrast-enhanced mammography) and, if needed, a needle biopsy on the same visit.

  • Does going to the clinic mean I have cancer?

    No. Around nine in ten lumps assessed in these clinics turn out to be benign, such as fibroadenoma, cyst, duct ectasia or fat necrosis.

  • How long do results take?

    Clinical and imaging findings are often discussed on the day. Biopsy results are usually shared at a follow-up appointment within five to seven working days.

  • What happens if the result is cancer?

    Your case is discussed at a breast MDT. You will have staging investigations, molecular subtyping and, where appropriate, genetic counselling before a personalised treatment plan is agreed with you.

Related content

Keep reading.